The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression

Endocrine-Related Cancer

Volumn 19, Issue 6, 2012, Pages

  Rose, David P ^a   Vona Davis, Linda ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTINEOPLASTIC AGENT; ESTROGEN; INSULIN; LEPTIN; SEX HORMONE BINDING GLOBULIN; STEROID RECEPTOR; VASCULOTROPIN;

ADIPOSE TISSUE; ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER RISK; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPERINSULINEMIA; PARACRINE SIGNALING; PROTEIN EXPRESSION; REVIEW;

ADIPOKINES; ANIMALS; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGENS; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; NEOVASCULARIZATION, PATHOLOGIC; RISK FACTORS;

EID: 84869207897     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0203     Document Type: Review

References (119)

1. American Cancer Society 2011 Cancer Facts and Figures 2010. Atlanta.
2. American Diabetic Association 2012 Diagnosis and classification of diabetes mellitus. Diabetes Care 35 (Suppl 1) S64-S71.
3. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Bonofiglio D, Bossi G, Covington KR, Fuqua SAW et al. 2012 Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Research 72 1416-1427. (doi:10.1158/0008-5472.CAN-11-2558)
4. Bartella V, Cascio S, Fiorio E, Auriemma A, Russo A & Surmacz E 2008 Insulin-dependent leptin expression in breast cancer cells. Cancer Research 68 4919-4927. (doi:10.1158/0008-5472.CAN-08-0642)
5. Belfiore A & Malaguarnera R 2011 Insulin receptor and cancer. Endocrine-Related Cancer 18 125-147. (doi:10.1530/ERC-11-0074)
6. Belfiore A, Costantino A, Frasca F, Pandini G, Mineo R, Vigneri P, Maddux B, Goldfine ID & Vigneri R 1996 Overexpression of membrane glycoprotein PC-1 in MDA-MB-231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. Molecular Endocrinology 10 1318-1326. (doi:10.1210/me.10.11.1318)
7. Belfiore A, Frasca F, Pandini G, Sciacca L & Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews 30 586-623. (doi:10.1210/er.2008-0047)
8. Bradley RL & Cheatham B 1999 Regulation of ob gene expression and leptin secretion by insulin and dexamethasone in rat adipocytes. Diabetes 48 272-278. (doi:10.2337/diabetes.48.2.272)
9. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L et al. 2000 Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. American Journal of Epidemiology 152 514-527. (doi:10.1093/aje/152.6.514)
10. Brown KA, Hunger NI, Docanto M & Simpson ER 2010 Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research and Treatment 123 591-596. (doi:10.1007/s10549-010-0834-y)
11. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R et al. 2010 Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Molecular Cancer Therapeutics 9 2652-2664. (doi:10.1158/1535-7163.MCT-10-0318)
12. Bulun SE, Chen D, Moy I, Brooks DC & Zhao H 2012 Aromatase, breast cancer and obesity: a complex interaction. Trends in Endocrinology and Metabolism 23 83-89. (doi:10.1016/j.tem.2011.10.003)
13. Burwinkel B, Shanmugam KS, Hemminki K, Meindl A, Schmutzler RK, Sutter C, Wappenschmidt B, Kiechle M, Bartram CR & Frank B 2006 Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. BMC Cancer 6 268. (doi:10.1186/1471-2407-6-268)
14. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J & Cao Y 2001 Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. PNAS 98 6390-6395. (doi:10.1073/pnas.101564798)
15. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F & Gromova I 2005 Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Molecular and Cellular Proteomics 4 492-522. (doi:10.1074/mcp.M500030-MCP200)
16. Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML & Draznin B 2001 Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. Journal of Biological Chemistry 276 38023-38028. (doi:10.1074/jbc.M106008200)
17. Cirillo D, Rachiglio AM, la Montagna R, Giordano A & Normanno N 2008 Leptin signaling in breast cancer: an overview. Journal of Cellular Biochemistry 105 956-965. (doi:10.1002/jcb.21911)
18. Costantino A, Milazzo G, Giorgino F, Russo P, Goldfine ID, Vigneri R & Belfiore A 1993 Insulin-resistant MDA-MB-231 human breast cancer cells contain a tyrosine kinase inhibiting activity. Molecular Endocrinology 7 1667-1676. (doi:10.1210/me.7.12.1667)
19. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS & Gregg EW 2006 Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29 1263-1268. (doi:10.2337/dc06-0062)
20. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Caron M, Atfi A, Cherqui G & Capeau J 2000 Insulin-mediated cell proliferation and survival involve inhibition of c-Jun N-terminal kinases through a phosphatidylinositol 3-kinase- and mitogen-activated protein kinase phosphatase-1-dependent pathway. Endocrinology 141 922-931. (doi:10.1210/en.141. 3.922)
21. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y & Pecquery R 2006 Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochemical and Biophysical Research Communications 345 271-279. (doi:10.1016/j.bbrc.2006.04.076)
22. Ding EL, Song Y, Manson JE, Rifai N, Buring JE & Liu S 2007 Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 50 2076-2084. (doi:10.1007/s00125-007-0785-y)
23. Dos Santos E, Benaitreau D, Dieudonne MN, Leneveu MC, Serazin V, Giudicelli Y & Pecquery R 2008 Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells. Oncology Reports 20 971-977.
24. Dowling RJ, Zakikhani M, Fantus IG, Pollak M & Sonenberg N 2007 Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 67 10804-10812. (doi:10.1158/0008-5472.CAN-07-2310)
25. Draznin B 2011 Mechanism of the mitogenic influence of hyperinsulinemia. Diabetology & Metabolic Syndrome 13 10. (doi:10.1186/1758-5996-3-10)
26. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard-Barbash R & McTiernan A 2011 Associations of insulin resistance and adiponectin with mortality in women with breast cancer. Journal of Clinical Oncology 29 32-39. (doi:10.1200/JCO.2009.26. 4473)
27. Fain JN & Madan AK 2005 Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release from human adipocytes. Metabolism 54 220-226. (doi:10.1016/j.metabol.2004.08.016)
28. Fasshauer M, Klein J, Neumann S, Eszlinger M & Paschke R 2002 Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 290 1084-1089. (doi:10.1006/bbrc.2001.6307)
29. Ferrara N 2001 Role of vascular endothelial growth factor in regulation of physiological angiogenesis. American Journal of Physiology. Cell Physiology 280 C1358-C1366. (doi:10.1159/000046610)
30. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE & Haffner SM 2006 The natural course of b-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55 1114-1120. (doi:10.2337/diabetes.55.04.06.db05-1100)
31. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S & LeRoith D 2010 Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocrine-Related Cancer 17 941-951. (doi:10.1677/ERC-10-0091)
32. Fischer S, Hanefeld M, Haffner SM, Fusch C, Schwanebeck U, Kohler C, Fucker K & Julius U 2002 Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetologia 39 105-110. (doi:10.1007/s005920200027)
33. Fruhbeck G 2006 Intracellular signaling pathways activated by leptin. Biochemical Journal 393 7-20. (doi:10.1042/BJ20051578)
34. Gallagher EJ & LeRoith D 2010 The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology and Metabolism 21 610-618. (doi:10.1016/j.tem.2010.06.007)
35. Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S & LeRoith D 2011 Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 31 3213-3222 (doi: 10.1038/onc.2011.495). (doi:10.1038/onc.2011.495)
36. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S & Surmacz E 2006 Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clinical Cancer Research 12 1447-1453. (doi:10.1158/1078-0432.CCR-05-1913)
37. Gillespie EF, Sorbero ME, Hanauer DA, Sabel MS, Herrmann EJ, Weiser LJ, Jagielski CH & Griggs JJ 2010 Obesity and angiolymphatic invasion in primary breast cancer. Annals of Surgical Oncology 17 752-759. (doi:10.1245/s10434-009- 0797-6)
38. Gliozzo B, Sung CK, Scala P, Papa V, Frasca F, Sciacca L, Giorgino F, Milazzo G, Goldfine ID, Vigneri R et al. 1998 Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway. Journal of Cellular Biochemistry 70 268-280. (doi:10.1002/(SICI)1097-4644(19980801)70:2〈268:: AID-JCB12〉3.0.CO;2-J)
39. Golden SH, Dobs AS, Vaidya D, Szklo M, Gapstur S, Kopp P, Liu K & Ouyang P 2007 Endogenous sex hormones and glucose tolerance status in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 92 1289-1295. (doi:10.1210/jc.2006-1895)
40. Goldfine ID, Maddux BA, Youngren JF, Reaven G, Accili D, Trischitta V, Vigneri R & Frittitta L 2008 The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. Endocrine Reviews 29 62-75. (doi:10.1210/er.2007-0004)
41. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B & Hood N 2002 Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology 20 42-51. (doi:10.1200/JCO.20.1.42)
42. Goodwin PJ, Ennis M, Bahl M, Fantus IG, Pritchard KI, Trudeau ME, Koo J & Hood N 2009 High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Research and Treatment 114 517-525. (doi:10.1007/s10549-008-0019-0)
43. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK & Hood N 2012 Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. Journal of Clinical Oncology 30 164-171. (doi:10.1200/JCO.2011.36.2723)
44. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V & Kevorkian JP 2008 Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes and Metabolism 34 (Suppl 2) S43-S48. (doi:10.1016/S1262- 3636(08)73394-9)
45. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL et al. 2009 Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 101 48-60. (doi:10.1093/jnci/djn415)
46. Gupta PB & Kuperwasser C 2006 Contributions of estrogen to ER-negative breast tumor growth. Journal of Steroid Biochemistry and Molecular Biology 102 71-78. (doi:10.1016/j.jsbmb.2006.09.025)
47. Haffner SM, Valdez RA, Morales PA, Hazuda HP & Stern MP 1993 Decreased sex hormone-binding globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. Journal of Clinical Endocrinology and Metabolism 77 56-60. (doi:10.1210/jc.77.1.56)
48. Haluzik M, Parizkova J & Haluzik MM 2004 Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiological Research 53 123-129. (Pubitemid 38525115)
49. Hernandez-Aya LF & Gonzalez-Angulo AM 2011 Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16 404-414. (doi:10.1634/theoncologist.2010-0402)
50. Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, Sun Y, Wu Q & Chen L 2007 Adipocytokines and breast cancer risk. Chinese Medical Journal 120 1592-1596. (Pubitemid 47595751)
51. Hursting SD, Nunez NP, Varticovski L & Vinson C 2007 The obesity-cancer link: lessons learned from a fatless mouse. Cancer Research 67 2391-2393. (doi:10.1158/0008-5472.CAN-06-4237)
52. Jiang ZY, He Z, King BL, Kuroki T, Opland DM, Suzuma K, Suzuma I, Ueki K, Kulkarni RN, Kahn CR et al. 2003 Characterization of multiple signaling pathways of insulin in the regulation of vascular endothelial growth factor expression in vascular cells and angiogenesis. Journal of Biological Chemistry 278 31964-31971. (doi:10.1074/jbc.M303314200)
53. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L & Renehan AG 2012 Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55 1607-1618. (doi:10.1007/s00125-012-2525-1)
54. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT et al. 2005 Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 12 1071-1082. (doi:10.1677/erc.1.01038)
55. Kabat GC, Kim M, Caan BJ, Chlebowski RT, Gunter MJ, Ho GY, Rodriguez BL, Shikany JM, Strickler HD, Vitolins MZ et al. 2009 Repeated measures of the serum glucose and insulin in relation to postmenopausal breast cancer. International Journal of Cancer 125 2704-2710. (doi:10.1002/ijc.24609)
56. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, Gapstur SM & Golden SH 2009 The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 94 4127-4135. (doi:10.1210/jc.2009-0910)
57. Katzenellenbogen BS & Norman MJ 1990 Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 126 891-898. (doi:10.1210/endo-126-2-891)
58. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A et al. 2004 Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer 111 762-771. (doi:10.1002/ijc.20315)
59. Larsson SC, Mantzoros CS & Wolk A 2007 Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 121 856-862. (doi:10.1002/ijc.22717)
60. Le Bacquer O, Shu L, Marchand M, Neve B, Paroni F, Kerr Conte J, Pattou F, Froguel P & Maedler K 2011 TCF7L2 splice variants have distinct effects on b-cell turnover and function. Human Molecular Genetics 20 1906-1915. (doi:10.1093/hmg/ddr072)
61. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C & Bjorntorp P 1991 Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM, 12-year follow-up of population study of women in Gothenberg, Sweden. Diabetes 40 123-128. (doi:10.2337/diabetes.40.1. 123)
62. Liu Y, Petreaca M & Martins-Green M 2009 Cell and molecular mechanisms of insulin-induced angiogenesis. Journal of Cellular and Molecular Medicine 13 4492-4504. (doi:10.1111/j.1582-4934.2008.00555.x)
63. Lundgren H, Bengtsson C, Blohme G, Lapidis L & Waldenstrom J 1990 Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabetic Medicine 7 407-413. (doi:10.1111/j.1464-5491.1990.tb01415.x)
64. Maiti B, Kundranda MN, Spiro TP & Daw HA 2010 The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Research and Treatment 121 479-483. (doi:10.1007/s10549-009-0591-y)
65. Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R & Belfiore A 2012 Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 153 2152-2163. (doi:10.1210/en.2011-1843)
66. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G et al. 2004 Adiponectin and breast cancer risk. Journal of Clinical Endocrinology and Metabolism 89 1102-1107. (doi:10.1210/jc.2003-031804)
67. Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E & Ando S 2001 Estradiol increases IRS-I gene expression and insulin signaling in breast cancer cells. Biochemical and Biophysical Research Communications 288 685-689. (doi:10.1006/bbrc.2001.5815)
68. McTernan PG, Anwar A, Eggo MC, Barnett AH, Stewart PM & Kumar S 2000 Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. International Journal of Obesity and Related Metabolic Disorders 24 875-881. (doi:10.1038/sj.ijo.0801254)
69. Merlo GR, Basolo F, Fiore L, Duboc L & Hynes NE 1995 p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. Journal of Cell Biology 128 1185-1196. (doi:10.1083/jcb.128.6.1185)
70. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA & Manson JE 2003 Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26 1752-1758. (doi:10.2337/diacare.26.6. 1752)
71. Mick GJ, Wang X & McCormick K 2002 White adipocyte vascular endothelial growth factor: regulation by insulin. Endocrinology 143 948-953. (doi:10.1210/en.143.3.948)
72. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S et al. 2007 Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Research 67 3945-3954. (doi:10.1158/0008-5472.CAN-06- 3105)
73. Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID & Belfiore A 1992 Insulin receptor expression and function in human breast cancer cell lines. Cancer Research 52 3924-3930.
74. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N & Saito Y 2003 Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia 46 1483-1488. (doi:10.1007/s00125-003-1221-6)
75. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Yagui K & Saito Y 2005 Roles of degree of fat deposition and its location on VEGF expression in adipocytes. American Journal of Physiology. Endocrinology and Metabolism 288 E1128-E1136. (doi:10.1152/ajpendo.00003.2004)
76. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y & Noguchi S 2003 Association of serum adiponectin levels with breast cancer. Clinical Cancer Research 9 5699-5704. (Pubitemid 37499493)
77. Mulligan AM, O'Malley FP, Ennis M, Fantus IG & Goodwin PJ 2007 Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Research and Treatment 106 39-47. (doi:10.1007/s10549-006-9471-x)
78. Naidu R, Yip CH & Taib NA 2011 Genetic variations in transcription factor 7-like 2 (TCF7L2) gene: association of TCF7L2 rs12255372(G/T) or rs7903146(C/T) with breast cancer risk and clinico-pathological parameters. Medical Oncology 29 411-417. (doi:10.1007/s12032-011-9837-8)
79. Norton L, Fourcaudot M, Abdul-Ghani MA, Winnier D, Mehta FF, Jenkinson CP & Defronzo RA 2011 Chromatin occupancy of transcription factor 7-like 2 (TCF7L2) and its role in hepatic glucose metabolism. Diabetologia 54 3132-3142. (doi:10.1007/s00125-011-2289-z)
80. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA et al. 2010 Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 70 741-751. (doi:10.1158/0008-5472.CAN-09- 2141)
81. Ogasawara M & Sirbasku DA 1988 A new serum-free method of measuring growth factor activities for human breast cancer cells in culture. In Vitro Cellular & Developmental and Biology 24 911-920. (doi:10.1007/BF02623902)
82. Osborne CK, Monaco ME, Lippman ME & Kahn CR 1978 Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in longterm tissue culture. Cancer Research 38 94-102. (Pubitemid 8253520)
83. Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, Mauro L, Morrone EG & Ando S 1996 Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells. Journal of Cancer Research and Clinical Oncology 122 745-749. (doi:10.1007/BF01209122)
84. Park D, Pandey SK, Maksimova E, Kole S & Bernier M2000 Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor. Biochemistry 39 12513-12521. (doi:10.1021/bi000995y)
85. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL & Wolff AC 2011 Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. Journal of Clinical Oncology 29 40-46. (doi:10.1200/JCO.2009.27.3011)
86. Perera CN, Chin HG, Duru N & Camarillo IG 2008 Lepin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression. Journal of Endocrinology 199 221-233. (doi:10.1677/JOE-08-0215)
87. Pfutzner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G & Forst T 2004 Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 27 682-687. (doi:10.2337/diacare.27.3.682)
88. Rensing KL, Houttuijn Bloemendaal FM, Weijers EM, Richel DJ, Buller HR, Koolwijk P, van der Loos CM, Twickler TB & von der Thusen JH 2010 Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? Diabetologia 53 966-970. (doi:10.1007/s00125- 010-1687-y)
89. Ribatti D 2011 Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Reviews 37 344-352. (doi:10.1016/j.ctrv.2011.02.002)
90. Rose DP 1993 Diet, hormones, and cancer. Annual Review of Public Health 14 1-17. (doi:10.1146/annurev.pu.14.050193.000245)
91. Rose DP, Komninou D & Stephenson GD 2004 Obesity, adipocytokines, and insulin resistance in breast cancer. Obesity Reviews 5 153-165. (doi:10.1111/j.1467-789X.2004.00142.x)
92. Sasano H, Suzuki T, Nakata T & Moriya T 2006 New development in intracrinology of breast carcinoma. Breast Cancer 13 129-136. (doi:10.2325/jbcs.13.129)
93. Sawatsri S, Samid D, Malkapuram S & Sidell N 2001 Inhibition of estrogen-dependent breast cancer responses with phenylacetate. International Journal of Cancer 93 687-692. (doi:10.1002/ijc.1399)
94. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R & Belfiore A 1999 Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18 2471-2479. (doi:10.1038/sj.onc.1202600)
95. Sepp-Lorenzino L, Rosen N & Lebwohl DE 1994 Insulin and insulin-like growth factor signaling are defective in the MDA-MB-468 human breast cancer cell line. Cell Growth & Differentiation 5 1077-1083. (Pubitemid 24312283)
96. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ et al. 2012 Prospective study on the role of glucose metabolism in breast cancer occurrence. International Journal of Cancer 130 921-929. (doi:10.1002/ijc.26071)
97. Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Ando S et al. 2007 Expression of nuclear insulin receptor substrate 1 in breast cancer. Journal of Clinical Pathology 60 633-641. (doi:10.1136/jcp.2006.039107)
98. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP et al. 2000 Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. International Journal of Experimental Diabetes Research 1 81-88. (doi:10.1155/EDR.2000.81)
99. Teng JA, Hou RL, Li DL, Yang RP & Qin J 2011 Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Hormone and Metabolic Research 43 519-523. (doi:10.1055/s-0031-1280780)
100. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, Hsu GC, Yu CP, Yu JC & Sun CA 2007 Anthropometric measures, plasma adiponectin, and breast cancer. Endocrine-Related Cancer 14 669-677. (doi:10.1677/ERC-06-0089)
101. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS & Hankinson SE 2007 Plasma adiponectin concentrations and risk of incident breast cancer. Journal of Clinical Endocrinology and Metabolism 92 1510-1516. (doi:10.1210/jc.2006-1975)
102. Uzzan B, Nicolas P, Cucherat M & Perret GY 2004 Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Research 64 2941-2955. (doi:10.1158/0008- 5472.CAN-03-1957)
103. Veikkola T & Alitalo K 1999 VEGFs, receptors and angiogenesis. Seminars in Cancer Biology 9 211-220. (doi:10.1006/scbi.1998.0091)
104. Vigneri P, Frasca F, Sciacca L, Pandini G & Vigneri R 2009 Diabetes and cancer. Endocrine-Related Cancer 16 1103-1123. (doi:10.1677/ERC-09-0087)
105. Vona-Davis L & Rose DP 2007 Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-Related Cancer 14 189-206. (doi:10.1677/ERC-06-0068)
106. Vona-Davis L & Rose DP 2009 Angiogenesis, adiponectins and breast cancer. Cytokine & Growth Factor Reviews 20 193-201. (doi:10.1016/j.cytogfr. 2009.05.007)
107. Vona-Davis L & Rose DP 2012 Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Current Diabetes Reviews 8 116-130. (doi:10.2174/ 157339912799424519)
108. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ & Xu A 2006 Adiponectin modulates the glycogen synthase kinase-3b/b-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Research 66 11462-11470. (doi:10.1158/0008-5472.CAN-06-1969)
109. Wang Y, Hua S, Tian W, Zhang L, Zhao J, Zhang H, Zhang W & Xue F 2012 Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. Gynecologic Oncology 125 734-741. (doi:10.1016/j.ygyno.2012.03.012)
110. Wauters M, Considine RV, Yudkin JS, Peiffer F, De Leeuw I & Van Gaal LF 2003 Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. Hormone and Metabolic Research 35 92-96. (doi:10.1055/s-2003-39054)
111. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE & Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. Journal of Clinical Endocrinology and Metabolism 86 1930-1935. (doi:10.1210/jc.86.5.1930)
112. Willard AL & Herman IM 2012 Vascular complications and diabetes: current therapies and future challenges. Journal of Opthalmology 2012 209538. (doi:10.1155/2012/209538)
113. Wolf I, Sadetzki S, Catane R, Karasik A & Kaufman B 2005 Diabetes and breast cancer. Lancet Oncology 6 103-111. (doi:10.1016/S1470-2045(05)01736-5)
114. Xue F & Michels KB 2007 Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. American Journal of Clinical Nutrition 86 s823-s835.
115. Yamagishi S, Kawakami T, Fujimori H, Yonekura H, Tanaka N, Yamamoto Y, Urayama H, Watanabe Y & Yamamoto H 1999 Insulin stimulates the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor.Microvascular Research 57 329-339. (doi:10.1006/mvre.1999.2145)
116. Zeggini E & McCarthy MI 2007 TCF7L2: the biggest story in diabetes genetics since HLA? Diabetologia 50 1-4. (doi:10.1007/s00125-006-0507-x)
117. Zethelius B, Byberg L, Hales CN, Lithell H & Berne C 2003 Proinsulin and acute insulin response independently predict type 2 diabetes mellitus in men-report from 27 years of follow-up study. Diabetologia 46 20-26. (doi:10.1007/s00125-002-0995-2)
118. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D & Yee D 2010 Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncology 29 2517-2527.
119. Zhou HH, Chin CN, Wu M, Ni W, Quan S, Liu F, Dallas-Yang Q, Ellsworth K, Ho T, Zhang A et al. 2009 Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. European Journal of Pharmacology 616 346-352. (doi:10.1016/j.ejphar.2009.06.057)